Asset Details
Do you wish to reserve the book?
Feasibility and safety of dose-dense modified docetaxel–cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Feasibility and safety of dose-dense modified docetaxel–cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study
Do you wish to request the book?
Feasibility and safety of dose-dense modified docetaxel–cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Feasibility and safety of dose-dense modified docetaxel–cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study
2015
Overview
Background
Docetaxel–cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1–21) represents a standard but toxic regimen for advanced head and neck cancer (HNC). We report a retrospective monocentric study evaluating the safety and the efficacy of a dose-dense modified TPF (mTPF) regimen (days 1–14) in patients with stage III–IV HNC.
Methods
Thirty-seven patients retrospectively included from May 2011 to May 2014 were treated with a bimonthly dose-dense mTPF regimen (40 mg/m
2
docetaxel, 40 mg/m
2
cisplatin or AUC2 carboplatin, folinic acid 400 mg/m
2
for 2 h, bolus 5-FU 400 mg/m
2
for 10 min and 5-FU 1,000 mg/m
2
/day) by continuous infusion over 46 h).
Results
Chemotherapy was used as induction or palliative treatment in 12 and 25 patients, respectively, with a median age of 60 years (range 46−83). Median follow-up time was 7.4 months (2.53–16.7 months). There was no intestinal toxicity in 25 patients (68 %). Grade 3–4 hematological toxicity was noticed for 5 (13.5 %) patients. Granulocyte-colony stimulating factor was used as primary prophylaxis in 30 patients (81 %). After at least 4 delivered cycles, complete responses, partial responses and stable diseases were reported in 5 (15 %), 13 (39 %) and 5 (15 %) of the 33 evaluable patients, respectively, yielding an objective response rate of 54.5 % (39 % for palliative chemotherapy and 90 % for induction chemotherapy).
Conclusion
Dose-dense mTPF (days 1–14) is safe and seems to be as effective as TPF (days 1–21). Future prospective trials are required to confirm our results.
Publisher
Springer Japan,Springer Nature B.V
Subject
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Carboplatin - administration & dosage
/ Cisplatin - administration & dosage
/ Female
/ Fluorouracil - administration & dosage
/ Granulocyte Colony-Stimulating Factor - therapeutic use
/ Head and Neck Neoplasms - drug therapy
/ Humans
/ Leucovorin - administration & dosage
/ Male
/ Medicine
/ Oncology
/ Studies
